Ligand Pharmaceuticals | LGND - Kapitał Własny I Rezerwy





Kapitał Własny I Rezerwy Zmiana Data
Agenus USD -221.22M 49.89M 2026-03
Amgen USD 9.19B 532M 2026-03
Anika Therapeutics USD 133.9M 9.56M 2026-03
Arrowhead Research USD 613.98M 45.56M 2026-03
Baxter International USD 6.04B 86M 2026-03
Bristol-Myers Squibb USD 20.07B 1.6B 2026-03
Eli Lilly USD 31.2B 4.66B 2026-03
Enanta Pharmaceuticals USD 126.59M 61.87M 2025-12
Enviri Corporation USD 233.18M 21.88M 2026-03
Gilead Sciences USD 23.52B 897M 2026-03
GlaxoSmithKline GBP 17.42B 1.05B 2026-03
Glaxosmithkline GBP 22.06B 360M 2025-12
Heron Therapeutics USD 9.14M 4.15M 2026-03
Insmed USD 704.85M 34.12M 2026-03
Intrexon USD 43.17M 75.33M 2024-06
Ionis Pharmaceuticals USD 491.41M 2.32M 2026-03
Karyopharm Therapeutics USD -292.93M 23.67M 2025-12
Ligand Pharmaceuticals USD 997.32M 19.89M 2026-03
MacroGenics USD 21.2M 34.39M 2026-03
Merck USD 45.88B 6.73B 2026-03
Pacira USD 653.89M 39.22M 2026-03
Pfizer USD 90.1B 3.63B 2026-03
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Veracyte USD 1.34B 34.83M 2026-03